BIRMINGHAM -- November 16, 2026 -- Molecular Designs has received U.S. FDA 510(k) clearance (K262789) for its SimplicityDx Panel FluA/FluB/RSV, the first FDA-cleared assay from the Alabama-based company, it announced on Nov. 13, 2026. The multiplex real-time RT-PCR test detects and differentiates influenza A, influenza B and respiratory syncytial virus (RSV) RNA in anterior nasal swab specimens in a single run, with an internal control as a fourth target.
Clearance limits the panel to CLIA high-complexity laboratories
The panel is for prescription use only. It is cleared for laboratories certified under CLIA to perform high-complexity tests, so labs without that certification fall outside the cleared use.
The specimens come from individuals with signs and symptoms of respiratory tract infection. Results are intended as an aid in differential diagnosis, alongside clinical, epidemiologic and laboratory findings.
The panel is the only FDA-cleared product in the portfolio the company describes. Its other products are labeled for research use only and are not for use in diagnostic procedures.
CEO Michael Clark said the clearance required manufacturing and quality systems that the team built itself. The company says it makes its products under GMP and ISO 13485:2016 quality standards.
Breakaway format lets labs run only the tests they need
Molecular Designs says the breakaway format allows labs to use only the tests required for each run, with minimal pipetting. The company says this reduces waste and simplifies inventory management, which it describes as useful for labs with staffing constraints or volumes that swing with respiratory season. It adds that the format also supports batch processing on higher-volume days.
The panel is designed to work with the company's Simplicity Dx Extraction products. Chief Scientific Officer Dr. Greer Massey says the format was developed with input from clinical lab teams.
The company did not disclose clinical performance data, pricing or a commercial availability date.